Oral compositions delivering therapeutically effective amounts of cannabinoids
Oral compositions provide delivery of cannabinoids to a subject. The oral compare chewable, fast- or slow-dissolving once placed in the mouth of a subject.
1. A composition consisting of:
about 0.1% to about 20% by weight hemp oil extract,
about 35% to about 80% by weight of a sugar alcohol, or a blend of sugar alcohols,
about 1% to about 20% by weight of flavoring,
about 0.1% to about 10% by weight of tableting lubricants and powder flow agents,
about 0.01% to about 2% by weight of intensive sweeteners, and
about 5% to about 25% of a gum base,
based on the total weight of the composition.
2. The composition of claim 1 , wherein the hemp oil extract comprises a cannabidiol (CBD), of about 0.1% to about 80% by weight, based on total weight of the hemp oil extract.
3. The composition of claim 1 , wherein the sugar alcohol or sugar alcohol blend comprise: sorbitol, isomalt, xylitol, maltitol, mannitol, erythritol or combinations thereof.
4. A composition for treating a disease or disorder associated with abnormal mitogen-activated protein (MAP) kinase activity or levels wherein the composition comprises hemp oil, sugar alcohol, a blend of sugar alcohols, a gum base, or combinations thereof, wherein the composition, based on the total weight of the composition, comprises:
about 0.1% to about 20% by weight hemp oil extract,
about 35% to about 80% by weight of a sugar alcohol, or a blend of sugar alcohols, and
about 5% to about 25% of a gum base.
5. The composition of claim 4 , wherein a disease or disorder associated with abnormal mitogen-activated protein (MAP) kinase activity or levels comprises: migraines, neuropathic pain, general pain, joint pain or combinations thereof.
6. The composition of claim 1 , wherein the tableting lubricants and powder flow agents comprise magnesium stearate, silicon dioxide, calcium stearate, stearic acid, talc, rice bran-based excipients, or combinations thereof.
7. A method of treating a disease or disorder associated with abnormal or increased mitogen-activated protein (MAP) kinase activity or levels in a subject, comprising: administering to a subject in need thereof, a gum-based composition for chewing, the composition consisting of:
about 0.1% to about 20% by weight hemp oil extract,
about 35% to about 80% by weight of a sugar alcohol, or a blend of sugar alcohols,
about 1% to about 20% by weight of flavoring,
about 0.1% to about 10% by weight of tableting lubricants and powder flow agents,
about 0.01% to about 2% by weight of intensive sweeteners, and
about 5% to about 25% of a gum base,
based on the total weight of the composition,
wherein the disease or disorder associated with abnormal or increased mitogen-activated protein (MAP) kinase activity or levels in the subject is selected from the group consisting of a neuroinflammatory disease or disorder, migraines, epilepsy, neuropathic pain, general pain, joint pain, head trauma, or combinations thereof.
8. The method of claim 7 , wherein the hemp oil extract comprises a cannabidiol (CBD), of about 0.1% to about 80% by weight, based on total weight of the hemp oil extract.
9. The method of claim 7 , wherein the sugar alcohol or sugar alcohol blend comprises:
sorbitol, isomalt, xylitol, maltitol, mannitol, erythritol or combinations thereof.
10. The method of claim 7 , wherein the tableting lubricants and powder flow agents comprise magnesium stearate, silicon dioxide, calcium stearate, stearic acid, talc, rice bran-based excipients, or combinations thereof.